Related Experiment Videos
Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells
Cristina Cellai1, Anna Laurenzana, Alessandro M Vannucchi
1Department of Experimental Pathology and Oncology, University of Florence, 50134, Firenze, Italy.
Abstract:
A pharmacological approach to neoplasia by differentiation therapy relies on the availability of cytodifferentiating agents whose antitumor efficacy is usually assayed first on malignant cells in vitro. Using murine erythroleukemia cells (MELCs) as the model, we found that WEB-2086, a triazolobenzodiazepine-derived PAF antagonist originally developed as an anti-inflammatory drug, induces a dose-dependent inhibition of MELC growth and hemoglobin accumulation as a result of a true commitment to differentiation. MELCs treated for 5 days with 1 mM WEB-2086 show greater than or equal to 85% benzidine-positive cells, increased expression of alpha- and beta-globin genes, and down-regulation of c-Myb. This differentiation pattern, which does not involve histone H4 acetylation and is abrogated by the action of phorbol 12-myristate 13-acetate, recalls the pattern induced by hexamethylene bisacetamide (HMBA). In addition to MELCs, human erythroleukemia K562 and HEL and myeloid HL60 cells are massively committed to maturation by WEB-2086 and, with some differences, by its analog, WEB-2170. This suggests that WEB-2086, structurally distant from other known inducers, might be a member of a new class of cytodifferentiation agents active on a broad range of transformed cells in vitro and useful, prospectively, for anticancer therapy due to their high tolerability in vivo.
Insights
WEB-2086, a novel PAF antagonist, effectively induces differentiation in various cancer cells, including murine erythroleukemia cells (MELCs) and human cell lines. This agent shows promise as a new class of cytodifferentiation therapy for cancer treatment with high tolerability.
Area of Science:
- Pharmacology
- Cancer Biology
- Cell Differentiation
Background:
- Differentiation therapy is a promising pharmacological approach to treating neoplasia.
- Cytodifferentiating agents are crucial for this therapy, with their efficacy typically assessed on malignant cells in vitro.
- Murine erythroleukemia cells (MELCs) serve as a valuable model for studying cytodifferentiation.
Purpose of the Study:
- To investigate the cytodifferentiating potential of WEB-2086, a triazolobenzodiazepine-derived PAF antagonist.
- To evaluate the efficacy of WEB-2086 in inducing differentiation in various cancer cell lines.
- To explore WEB-2086 as a potential new class of anticancer therapeutic agents.
Main Methods:
- Murine erythroleukemia cells (MELCs) were treated with WEB-2086 to assess growth inhibition and hemoglobin accumulation.
- Benzidine staining, globin gene expression analysis, and c-Myb down-regulation were used to confirm differentiation.
- Human erythroleukemia (K562, HEL) and myeloid (HL60) cells were also treated with WEB-2086 and its analog WEB-2170.
Main Results:
- WEB-2086 induced dose-dependent inhibition of MELC growth and hemoglobin accumulation, indicating true commitment to differentiation.
- Treatment resulted in over 85% benzidine-positive cells, increased alpha- and beta-globin gene expression, and c-Myb down-regulation.
- WEB-2086 and WEB-2170 induced significant maturation in human K562, HEL, and HL60 cell lines.
Conclusions:
- WEB-2086 acts as a potent cytodifferentiation agent, distinct from known inducers, and is effective across multiple cancer cell types in vitro.
- The differentiation pattern induced by WEB-2086 does not involve histone H4 acetylation.
- WEB-2086 represents a potential new class of cytodifferentiation agents with prospective anticancer therapeutic applications due to its broad activity and high in vivo tolerability.